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Summary: 
Introduction: Good adherence to ART is known to be extremely important for successful 
suppression of HIV viral load and to improve clinical outcomes in children. However, high rates 
of adherence, greater than 95%, are needed to achieve these goals. Therefore it is important 
that clinical and support staff who work with caregivers and their HIV children understand the 
importance of good adherence and convey this message to their patients. To do this, we need 
a foundation of knowledge with which to base an adherence theory on and an understanding of 
the barriers and facilitators to ART adherence. Though much work on understanding ART 
adherence has been done in developed settings, the majority on adults, there continues to be a 
paucity of research and lack of guiding theory regarding ART adherence in children in resource 
limited settings. This is a significant problem, as the number of children living with HIV in 
resource limited settings continues to grow, especially in places like sub-Saharan Africa which 
accounts for 90% of all children living with HIV. Recent scale-up efforts of ART to children in 
resource limited settings means that adherence has become a highly salient issue. Studies to 
date on pediatric ART adherence in resource limited settings incorporate a wide array of study 
populations, study designs, adherence measurement strategies, and definitions of adherence. 
Drawing conclusions from these studies and development of a culturally appropriate adherence 
theory has been difficult. Prior studies recommend that more qualitative, formative research will 
be helpful in the development of such an adherence theory and to help inform the design of 
more uniform future studies. 
Systematic Review: 
Objectives: This paper includes a systematic review (Section II) of qualitative research 
assessing pediatric ART adherence in resource limited settings. The objective was to obtain a 
better understanding of what types of qualitative literature exist regarding ART adherence in 
children in resource limits settings, along with their contributions to the literature. 
Methods: I searched online bibliographic databases, including MEDLINE, EMBASE, NLM, 
Cochrane Database, and various conference abstract databases using systematic criteria. 
Studies were selected for review that used qualitative methods to assess ART adherence in 
children less than 18 years of age in resource limited settings. The qualitative findings were 
extracted and summarized. 
Results/Discussion: The review found 4 studies which incorporated qualitative methods and 
made an assessment of ART adherence in children in resource limited settings. Only 2 of the 4 
studies were rated as 'good' quality and each differed in their methods and study populations. 
No pooled assessment of the results could be made due to the heterogeneity of studies. 
However, major themes which were commonly cited as barriers to adherence include poor 
caregiver-child relationships and structural barriers such as cost, access, and transportation. 
Common facilitators of adherence included having a support system for the child or caregiver 
and the development of an adherence strategy that both the child and caregiver can rely on. It 
is clear more such studies of high quality are needed to confirm the results of these studies and 
to add to our understanding of this topic. 
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Research Plan: 
Objectives/Rationale: A research plan was developed to add to our general understanding of 
why ART regimens are difficult for children in resource limited settings (Section Ill). The 
objective of this plan was to inform more accurate measurement of adherence and the 
development of culturally appropriate best practice ART adherence guidelines. Since little data 
exists on adherence to pediatric ART regimens in resource limited settings, the Kalembe Lembe 
(KLL) Pediatric Hospital in Kinshasa, Democratic Republic of the Congo represents a prime 
target for farther study. Little information exists regarding adherence in Kinshasa. To date, 
direct assessment of pediatric adherence at KLL has yielded rates well above expected norms 
of children in similar settings and lack expected variability of adherence rates between subjects. 
Qualitative methods represent a sensible place to begin study in a new setting. They can be 
used to inform the development of more valid, culturally appropriate adherence measures and a 
contextual adherence theory, as well as provide more in-depth information than quantitative 
studies alone. 
Methods: This plan called for a set of 40 qualitative interviews to be administered to HIV positive 
children taking ART regimens and their caregivers at the KLL Pediatric Hospital. An interview 
script for adults, HIV status disclosed children, and HIV status non-disclosed children were 
developed to assess barriers and facilitators to ART adherence in this setting. Demographic 
information were also collected. Interviewers were trained and interviews were recorded for 
transcription and translation into English. IRB approval was obtained and the project was begun 
in June of 2009. Analysis of results will take place following completion of the study. 
Feasibility of Research Plan and Lessons Learned: 
Experiences with implementation of research plan and lessons learned during this process are 
outlined in the last section (Section IV). Working in foreign settings can be quite challenging. 
Language barriers and the constraints of working in a resource limited setting were the most 
difficult aspects. International research requires a good understanding of the needs of a 
population in a given locale and a strong awareness of the infrastructure available to perform a 
particular study. To overcome such barriers, it requires good communication and collaboration 
with local colleagues. Planning for such projects should not be rushed. The timeframe and 
budgeting of such projects will likely require the most preparation. Overall, this research plan 
was feasible and the lessons learned in implementing this plan were valuable. 
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I. Introduction 
1. Background 
General Overview: 
There are over 2.1 million children world-wide living with HIV/AIDS.1 With 370,000 new 
infections in 2007, this number is continuing to grow, especially in places like sub-Saharan 
Africa, which accounts for 90% of all children living with HIV.1 Fortunately, over the past decade 
many low and middle income countries have made commitments to scale up antiretroviral 
therapy distribution to children. This is partly due to the World Health Organization's (WHO) 
'3x5' initiative and the Joint United Nations Program on HIV/AIDS (UNAIDS) initiatives for 
children, which has a goal to provide ART or cotrimoxazole prophylaxis therapy to at least 80% 
of children in need by 2010. 
Progress has been made to increase availability of ART in these settings, thanks to 
increased advocacy along with the decreasing price of drugs and a focus on infrastructure for 
pediatric care. In 2007, nearly 200,000 children received ART in resource limited settings, 
compared with only 75,000 in 2005.2 Within the past 5 years, the US President's Emergency 
Plan for AIDS Relief (PEPFAR), the Global Fund to Fight AIDS, Tuberculosis and Malaria, the 
Clinton Foundation, and the international drug purchase facility, have all made significant 
financial and technical contributions to scaling up pediatric HIV treatment.' This has allowed 
ART to reach children in even the most remote parts of the world. 
The push for higher rates of pediatric ART stems from data that show treatment in both 
HIV positive adults and children can reduce viral load, significantly improve mortality rates, and 
can improve quality of life?5 In resource limited settings, ART has been shown repeatedly to 
improve clinical outcomes in children, including the initiation of early treatment in infants.2• 6 
Without access to ART, prognosis of HIV infected individuals is poor.7 
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Despite the improved availability of ART drugs, adherence remains a problem. ART 
regimens are complicated for children. While once a day combination dosing is available to 
adults and older adolescents in some resource limited settings, younger children are typically 
still on standard therapy with three different drugs. Syrups and solutions are necessary for 
treating infants and young children who cannot swallow pills. However, these have 
shortcomings, which may include limited availability, high cost, storage difficulties, reduced 
shelf-life, and alcohol excipient or solutions leading to poor palatability. Many other drugs do 
not have pharmokinetic data on, or formulations suitable for, pediatric dosing.8 Often regimens 
may require up to 4 doses per day, making routine administration difficult. Fortunately, pediatric 
fixed dosed regimens and combination ART are becoming more widespread in resource limited 
settings. 
ART Adherence in Children: 
Accurately measuring ART adherence in children is extremely important, as it is critical 
to know the frequency of, and reasons behind, first line ART regimen failures. How often do 
these regimens fail? Further, is it because first line treatments develop resistance and have 
become ineffective in reducing viral load levels, or are failure rates due in large part to non-
adherence of these mediations? In the latter case, unnecessary switches to expensive 
alternate or second line regimens may occur, resulting in a failure to address the underlying 
problem. Without an understanding of true adherence rates and barriers to good adherence, 
addressing failure of treatment regimens in children becomes a difficult process. 
It is known that high levels of ART adherence are required for successful treatment of 
HIV. Studies show that at least 90% to 95% adherence to ART regimens is needed for optimal 
virologic suppression and to minimize failure rates.9•11 This level of adherence is recommended 
by the current pediatric ART guidelines in Africa. 12 In one highly cited study, 81% of those with 
>95% adherence recorded complete virologic suppression, compared with only 64% of those 
with 90-95% recorded adherence.10 Virologic suppression decreased significantly with 
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continuing decline of adherence rates. Without adequate adherence to ART, viral resistance, 
opportunistic infections and ultimately failure of therapy can result.13.15 
Adequate adherence to pediatric ART regimens is possible in low and middle income 
countries. 16 In some instances, adherence is equal to or better than rates in higher income 
countries, where children typically receive increased support and less complex regimes. 16 
However, in many instances adherence rates are still sub-optimal. Reported rates vary from as 
low as 49% adherence up to 1 00% adherence rates. In one well conducted systematic review of 
17 articles assessing pediatric adherence in low and middle income countries, 13 articles 
reported > 75% adherence rates in their study cohort, although only 5 reported >=95% 
adherence.16 Given that 3 of those 5 studies reporting >95% adherence were patient or 
caregiver self reports of 100% adherence and did not employ any validation strategies on 
measurement, it is likely these are overestimates. This review and its findings are addressed in 
greater detail in the Literature Review: Overview section (Part 1: Introduction, Section 2). 
Accurate assessment of adherence in these settings is much more difficult without ready 
access to objective testing measures, such as viral load or CD4 counts. Though a number of 
low tech measurement techniques for ART adherence in resource limited settings exist, it is not 
known which are most reliable or accurate. Evidence suggests that more invasive techniques of 
measuring adherence tend to yield lower rates of adherence.17"19 For instance, studies 
implementing pill counts to determine adherence rates report lower rates than those where 
clinicians rely on self reported adherence rates during interviews or follow-up visits. 
Unannounced home pill counts and Medication Event Monitoring System (electronic 
measurement) yield even lower numbers.17• 19 This suggests that there is a significant recall 
bias or social desirability bias present when children and their caregivers are directly asked 
about medication regimens. Therefore, directly asking about adherence may not be an optimal 
strategy for the accurate measure of adherence. 
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Measurement of ART adherence is thought to be much more complex in children 
compared with adults, as good adherence often depends on many additional factors. 16• 2° For 
instance, adherence factors in children can be extremely variable depending on age. Younger 
children will depend more heavily on the caregiver, whereas older children gain autonomy and 
become increasingly responsible for taking their own medication as they age. 
Unfortunately, both younger children and older adolescents may not be aware of their 
HIV infection, and may not be well informed of the rationale behind taking such a complex 
regimen of medication. Estimates of HIV status disclosure to children in sub-Saharan Africa 
range from 75% to as low as 20%.21 Often caregivers who present to the clinics are not the 
primary care giver at home, making assessment and understanding of poor ART adherence 
during routine clinic visits challenging. Due to these complex issues there is little consensus on 
what underlying factors contribute most to pediatric ART adherence in resource limited 
settings.16 
While numerous studies in adults have been undertaken to better understand adherence 
in these settings, studies in children have been sparse. To date, quantitative studies in children 
looking at factors predicative of non-adherence are variable in both their methods and results. 
Definitions for what is meant by 'adherent', factors measured, and analyses vary widely among 
published studies. At this time there appears to be a lack of guiding theory in pediatric ART 
adherence research and no reliable predictors of non-adherence have been established.16• 22.24 
Aims of the Paper: 
Adherence to pediatric ART regimens has not been well characterized in resource 
limited settings. A better understanding of barriers and facilitators of adherence is needed to 
allow development of more accurate measures of adherence. 
I will conduct a systematic literature review (Section II: Systematic Review) to determine 
what we understand about pediatric ART adherence, focusing on studies that incorporate 
qualitative methodologies. As I will describe in the next sections, the lack of guiding theory in 
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assessing pediatric ART adherence in resource limited settings justifies the need for a 
qualitative study. 
This paper will also outline a research plan (Section Ill: Research Plan) for a qualitative 
research study incorporating in-depth, semi-structured interviews to assess pediatric ART 
adherence at the Kalembe Lembe Pediatric Hospital in Kinshasa, Democratic Republic of the 
Congo. During the course of the paper I will travel to Kinshasa and work to implement this 
research plan. Also, I will describe the feasibility of implementing qualitative research in 
resource limited settings and lessons learned during the experience (Section IV: Implementation 
of Research Plan and Lessons Learned). 
It is the hope that information gathered frorn this systematic review and research plan 
will ultimately inform the design of future studies so we can continue to better understand, 
measure, and ultimately help provide best practice guidelines for improving pediatric ART 
adherence in Kinshasa and in other resource limited settings. 
2. Literature Review: 
Overview: 
The majority of literature available on pediatric ART adherence in resource limited 
settings appears to exist in the form of quantitative studies that incorporate statistical methods 
to determine correlates to non-adherence. The most recent published systematic review on 
children over viewing this type of literature was completed by Vreeman and colleagues in 
2007.16 Their study revealed 17 published studies on this topic. Their aim was to 'compile and 
critically analyze pediatric ART adherence measurement in resource limited settings to inform 
adherence monitoring strategies' and to provide 'measurement techniques, adherence 
estimates, and clinical correlates to inform ART adherence monitoring. 
Their search strategy included MEDLINE, EMBASE, bibliographic searches and relevant 
websites, such as those of the WHO, United Nations Children's Fund, and the International 
AIDS Society covering dates from January 151, 1966 to September 131h, 2007. Populations 
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assessed were children 18 years of age or less, though some studies also incorporated adults 
as study subjects. Countries included were those of low and middle income as defined by the 
World Bank.25 All articles were in English and displayed a 'descriptive interventional study 
describing non-pregnant, HIV positive children that measured ART adherence'.16 No 
assessment of quality was undertaken for these studies, other than the initial inclusion criteria. 
They noted some studies were 'reasonably well done' while others 'did not have ideal 
methodological strength'. 
Their results reveal studies on pediatric ART adherence in resource limited settings 
incorporate a wide array of study populations, study designs, adherence measurement 
strategies, and definitions of adherence. Strategies for measuring adherence within the studies 
included self or caregiver reports, pill counts, pharmacy records, clinic attendance, or serum 
drug levels. No studies used direct clinical indicators, such as CD4 count or viral load, to 
assess adherence, nor did they correlate adherence with direct clinical outcomes. 
Definitions of 'adherent' varied among studies and prevented the authors from pooling 
results or conducting a meta-analysis of correlates to adherence. The definition used for 
'adherent' is an especially important distinction in statistical analyses, where subjects must be 
defined as either adherent or non-adherent. Further, adherence rates were assessed over 
different time spans, ranging from 1 to 30 days. 
Only 6 of the 17 studies within the Vreeman eta/. review were specifically designed to 
identify predictors of non-adherence. General themes arose among the studies; however there 
were few consistencies among all 6 studies. To overview their findings, the studies reveal 
familial and social factors to be most predictive of non-adherence. These are living in rural 
settings, disorganized biologic families, low parental education, living in poverty, experiencing of 
stigma, and lack of caregiver availability. Reported instances of non-adherence included 
conflicts between the child and parent, having multiple adults involved in pill supervision, and 
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non-disclosure of the child's HIV status. Several of the studies also point out that complicated 
regimens, medication side effects, and high costs are also likely correlated with non-adherence. 
Overall, Vreeman and colleagues conclude that due to the heterogeneity of the studies 
included in their review, it is difficult to draw any broad conclusions on best measurement 
techniques, best definition of 'adherent', best time frames in which to assess adherence, or 
predictive correlates to adherence. They also note that none of the studies reported any efforts 
to develop adherence measures using qualitative techniques to test these items and ensure 
cultural relevance and validity, nor do they confirm cross cultural validation of item translation. 
The review supports the notion that implementing systems to monitor pediatric ART 
adherence remains highly important. However, a comprehensive theory of pediatric ART 
adherence research is needed to guide future investigations of predictors of adherence. 
Vreeman recommends qualitative formative research will be useful in these settings to inform 
the development of more valid, culturally appropriate measures and a contextual adherence 
theory. 
Since the Vreeman eta/. review, few additional studies on pediatric adherence in 
resource limited settings have been published. One prospective cohort study from South Africa 
in 2008 used medication return (MR) to measure adherence, coupled with viral and immune 
responses to treatment.20 This was assessed over a period of one year. 'Adherent' was defined 
as >=90% of medication taken (ie <1 0% returned). The study found access to water and 
electricity as well as caregivers having secondary education or higher was associated with 
being adherent. Also, the MR method appeared to correlated well with viral load and CD4 count 
testing. In another study conducted in Togo from 2008, 'adherent' was defined as no caregiver 
reported missed doses in the past 4 days.26 They found that female gender, living in an 
individual setting, receiving other than NNRTI-based regimen and caregivers' perceived difficulty 
of ART administration were associated with non-adherence. 
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There are several other studies similar studies published on children in resource limited 
settings. Though these studies do yield valuable information for their settings, they still face the 
same problems noted in the Vreeman eta/. review. That is, heterogeneity of methods and 
variables measured, varying definitions of what is meant by 'adherent', and the clear 
heterogeneity of findings using logistic regression of dichotomous variables. This continues to 
support the assertion that an improved theory on pediatric adherence is needed to guide future, 
and more uniform, research. 
There has been some work done on development of adherence theory in adults in the 
USA. Adamian et a/.27 worked to combine the more than 200 variables that have been used to 
assess and measure adherence in past studies and boil this down into simplified categories of 
factors relating to the person, practitioner, the regimen itself, and socio-environmental factors. 
They used 'social cognitive theory with empirical studies of ART adherence' to ultimately 
suggest that patients' adherence is affected by both their motivation and self-efficacy, or 
confidence in their ability, to take the medication. They developed a figure which takes into 
account these major categories, as seen in Figure 1. 
Figure 1. Conceptual model of factors affecting adherence to antiretroviral therap/7 
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Ware et a/."8 were able to take adherence theory and provide guidelines for application 
to resource limited settings. They introduce a heuristic schema for examining the validity of 
conceptual models of adherence, such as that of Adamian eta/., in these settings. They note 
that for an adherence model to be socially and culturally valid it must 'accurately and 
comprehensively represent the dynamics of adherence for a socially and/or culturally defined 
group.'28 To do this, we should ask if current models are relevant to resource limited settings, if 
the basic concepts are important and meaningful to the resource limited setting, and is the 
complexity of adherence captured in the new setting. If the answer is no to any of these, 
formative research is likely needed to develop an appropriate model or theory for a particular 
setting. 
Both Adamian eta/. and Ware eta/. provide extremely helpful insights into 
understanding adherence and the theory that should go behind any future assessment. 
Unfortunately no current adherence theory takes into account the complexities of dealing with 
children, nor do they take into account the social and cultural complexities of resource limited 
settings. Farther complicating things, not all resource limited settings are equal and may in fact 
present very different realities for the people who live in one setting versus another. This again 
supports the need for more qualitative formative research in these settings. 
Qualitative Literature Overview: 
Several recent reviews of ART adherence literature that focus on studies with qualitative 
methodology currently exist. Mills eta/. conducted a review of both quantitative and qualitative 
studies on adherence to highly active ART (HAART) in both developed and developing 
countries.29 Their review revealed 37 studies with qualitative methodology. However, only two 
were performed in developing countries and neither of these looked at children. 
Overall, the study found recurring themes within the categories of patient related barriers, 
beliefs about medication, and daily schedules. A fear of disclosure, forgetfulness, a lack of 
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understanding of treatment benefits, complicated regimens, and being away from their 
medications were consistent barriers to adherence across developed and developing nations. 
The most common barriers to adherence from the two studies undertaken in resource 
limited settings (Botswana, Brazil) were issues of access, including financial constraints and a 
disruption in access to medications. Other barriers which arose in developing countries were co-
existing substance addiction, a basic matter of forgetting, financial constraints, complaints of 
bad taste, side effects, not feeling like the medications were working, trouble incorporating work 
and family responsibilities with HAART, and difficulties with complex HAART regimens. While 
themes overlap with those in the high income countries, it is clear that external and structural 
factors tend to play a larger role in developing countries. 
Simoni et at. conducted a review of literature on ART adherence, specifically focusing on 
children.30 They found 50 studies that address this topic in children; however the majority gives 
only an estimate of adherence rates or quantitative analyses of correlates to adherence. Only 
two of these studies reported using qualitative methods and neither study took place in a 
resource limited setting. Regardless, they found that many factors in children are similar to 
those of adults found in the Mills et at. review, namely fear of social stigma related to HIV 
disclosure, complexity of the regimen, adverse effects, forgetfulness, absence of 
symptomatology, or the thought of not needing to be on ART because they feel healthy. 
However, there are issues specific to children. For instance, some factors are unique to 
the developmental stage of the child or adolescent. Often youths will focus on gaining rewards 
and 'living in the moment', hence there is much less concern on planning for the future. 
Therefore a conscious decision not to take medications is often made.31 For the younger 
children who may not make the decision themselves, caregiver adherence depends on 
acceptance of the disease and the perceived benefits of treatment for their child. The stronger 
the disease acceptance and perceived treatment benefits, the more likely they were to adhere 
to treatment regimens for their children. Data also suggest the ability to cope well with HIV may 
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be a strong correlate to adherence, which underscores the impotence of psychosocial well 
being in children with HIV.31 • 32 
No reviews found focused solely on caregivers of HIV positive children. However a 
number of qualitative studies have been published regarding ART adherence of caregivers, 
though these studies have been concentrated in developed settings, such as the USA and 
Europe.31 • 33• 34 It's clear caregivers play a huge role in maintenance of good adherence for their 
children. The main factors which appear to influence adherence include the caregiver-child 
dynamic, the caregiver's attitudes and feelings towards HIV and ART, and knowledge and 
understanding of the disease and the importance of treatment. It is also clear that the younger 
the child, the more responsibility the caregiver has in maintaining good adherence. 
Overall, there was very little qualitative literature to be found by conducting general 
literature searches on pediatric ART adherence in resource limited settings. A more systematic 
approach may be needed to understand what type of literature exists on this topic and if 
additional studies are needed in this area. Additional literature may be difficult to find however, 
which justifies the need for a systematic review with a robust search strategy and methods. 
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II. Systematic Review 
Introduction: 
To gather a broader understanding of barriers and facilitators of adherence to ART in 
resource limited settings, I undertook a systematic literature review to assess barriers and 
facilitators of adherence in the pediatric population. Because prior reviews had been largely 
unable to draw broad conclusions from quantitative analyses of correlates to non-adherence, 
the aim of this review was to obtain a better understanding of what types of qualitative literature 
exist regarding ART adherence in children in resource limits settings, along with their 
contributions to the literature. 
Studies which incorporate qualitative methods have the ability to access information that 
is often missed in quantitative studies alone. They are able to describe challenges, barriers, 
and facilitators in ways that cannot be characterized by simple surveys or from statistical 
analyses on a myriad of dichotomous variables. These types of studies are useful to better 
understand how patients take ART, what their beliefs and perceptions are about these drugs 
and their disease, as well as to characterize the lived experiences of those patients on ART.22 
Qualitative methods can also be used to confirm the validity of quantitative analyses of barriers 
to adherence or interventions which address adherence. 
At present, there is a 'tremendous paucity of qualitative research in developing settings' 
that characterizes barriers or facilitators to ART.29 Though prior reviews on qualitative literature 
have been helpful in shaping our understanding of barriers and facilitators of ART, we are 
unable to generalize these findings to children in resource limited settings. Since no published 
reviews to date have specifically focused on this, this review will aim to do so. 
The literature on pediatric ART adherence has been largely atheoretical to date.35 This 
review will also attempt to take findings from papers which meet inclusion criteria and 
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synthesize them into a broader set of conclusions which may give some additional theoretical 
background with which to base future qualitative and quantitative research. 
Methods: 
To understand how qualitative methods have been used in pediatric ART adherence 
research in resource limited settings and conclusions these studies have drawn, several 
bibliographic databases were searched. These included PubMed (MEDLIN E), EM BASE, the 
Cochrane Library, and other relevant websites such as those for the WHO, UNAIDS, and the 
International AIDS Society. Both English and French language articles were included in the 
search, since many resource limited settings across the world speak French or English as their 
primary languages. Search dates ranged from January 1 ", 1990 through the present (March 
15'h, 2009), since ART was essentially unheard of in resource limited settings before the mid-
nineties. Conference abstracts from international conference the web sites of the International 
AIDS Society (inception to 2008) and Conferences on Retroviruses and Opportunitistic 
Infections (inception to 2008) were also searched, as well as the National Library of Medicine 
(NLM) Abstract Database. Other inclusion criteria can be summarized in Table 1. 
The following search strategy was used: (pediatric OR paediatric OR infant OR child OR 
adolescent OR teen OR teenager) AND ((antiretroviral OR anti-retroviral AND agent) OR 
antiretroviral agent* OR ART OR HAART) AND (compliance OR adherence OR patient 
compliance OR patient dropout OR barrier OR facilitator) AND (qualitative OR anthropology, 
cultural OR interviews OR interviews as topic OR chart review OR ethnography OR 
ethnographic OR narrative OR conversation). The MeSH terms included in this search were: 
infant, child, adolescent, patient dropouts, compliance, cultural anthropology, and interviews. 
However the keyword search was more robust than searches utilizing MeSH headings alone. In 
addition to the electronic search, the bibliographies of relevant articles identified in the search 
were reviewed by hand and experts in the field were consulted. 
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For inclusion, articles must have used some form of qualitative methodology for 
assessment of adherence to ART regimens in non-pregnant, HIV positive children less than 18 
years of age or of their caregivers. Types of qualitative research included interviews, focus 
groups, ethnography, or textual analysis (medical record review, other document review, 
visual/art representations, or vignettes/conversations). The study settings must also have been 
a low or middle income country as classified by the World Bank [World Bank website].25 
included studies if they described any individuals less than 18 years of age, even if they 
included adults as well. Studies that focused on Prevention of Mother to Child Transmission 
(PMTCT) or post-exposure prophylaxis were excluded. There was no exclusion criteria based 
on the time frame of the study or number of subjects included. 
I analyzed each article to determine study characteristics, study setting, and types of 
qualitative methodology to determine if they met the inclusion criteria. If the studies met 
inclusion criteria, they were further analyzed for themes which arose in the qualitative 
methodology and overall conclusions of studies. Though this process was performed by only 
one person, ideally this process would include two individuals for reviewing and assessing the 
articles. 
To assess paper quality, I devised a rating scale of good, fair, and poor. Since there are 
no universally accepted guidelines for assessing qualitative literature, I based these guidelines 
on several different sources.29· 36• 37 The criteria is primarily based on the 'RATS' criteria, which 
focus on the relevance of the study question, appropriateness of the qualitative method, 
transparency of procedures, and soundness of the interpretive approach. Quality criteria and 
the rating scale are summarized in Table 2. 
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Table 1. Study Inclusion & Exclusion Criteria 
Pediatric ART Adherence Papers 
incorporating Qualitative Methodology in 
Resource Limited Settings 
Inclusion: 
Exclusion: 
Dates: 
Ages: 
Settings: 
Languages: 
Research 
Designs: 
Topics: 
1990-present 
0-17 Years 
Low and Middle Countries 
as defined by the World 
Bank 
English, French 
Interviews: 
Semi-structured 
Open-ended 
Focus Groups 
Ethnography 
Textual Analysis 
PMTCT 
Post-Exposure 
Prophylaxis 
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Table 2. Quality assessment criteria 
Quality Rating Assessment Criteria 
Good: Meets at least 8 
Good Criteria: 
Fair: >3 Good criteria 
missing; <=2 Red Flags 
Poor: >3 Good criteria 
missing; >2 Red Flag 
Results: 
Good Criteria 
• Research question explicitly stated and justified 
• Qualitative design described 
• Justification for qualitative design given 
• Criteria for selecting study sample justified and explained 
• Details of recruitment procedures and of those who 
declined to participate described 
• Methods outlined with details on development given 
• Examples of methods given 
• Roles of researchers explicitly stated and potential existing 
biases discussed 
• Confidentiality of subjects addressed 
• Analytic approach discussed in depth, usually with multiple 
reviewers of the qualitative data 
• Findings discussed with reference to expositing theoretical 
and empirical literature 
Red Flags 
• Accounts simply analyzed for content, no complex theory 
generating approach taken 
• No justification or in-depth description of methods 
• Findings anecdotal or self-evident in nature 
• Findings generally full of jargon or trite in nature 
• Researcher has multiple roles, not thoroughly discussed 
potential biases or maintenance of objectivity 
• Ethics of study not addressed 
• Recruitment of consent of study subjects thinly discussed 
The systematic literature search identified 445 articles and abstracts. The online search 
of PubMed yielded 349 articles and the search of EMBASE yielded 45 articles, 18 of which were 
not found by the PubMed search. The Cochrane Library Database yielded 6 articles, though 
none of which dealt with resource limited settings. National Library of Medicine and conference 
abstract databases yielded 56 additional potential sources for review. This strategy resulted in a 
total of 428 unique articles and abstracts. 
All 428 abstracts were reviewed. I immediately excluded articles which did not obviously 
address ART adherence or were solely focused on adults. This left 53 articles that all 
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underwent a full text review to confirm the methods used and the location of the studies. If 
studies did not employ a type of qualitative methods or take place in a resource limited setting, 
they were excluded. 49 additional studies did not meet criteria, which left 4 studies employing 
qualitative methods addressing ART adherence in children in a resource limited setting. Each 
was published between 2005 and 2008, which tends to mark the dramatic increase made in the 
provision of ART to children in resource limited settings during the last 5 years. The review 
process is outlined in Figure 2. 
Figure 2. Article Selection Flow Chart 
Articles Found: 455 
• 349 PubMed 
-45 EMBASE 
- 5 Cochrane Library 
- 56 NLM & Conference Abstract 
Search 
Excluded: 
- 27 Non-Unique 
Abstracts Reviewed: 428 
or Repeat Articles 
• 349 PubMed 
-18 EMBASE 
- 5 Cochrane Library 
·56 NLM Abstract Search 
Excluded: 
• 331 Not Related 
Full Text Review: 53 
to Adherence 
• 44 In Adults 
36 PubMed Only 
5 EMBASE 
12 N LM Abstract Search (Full text 
not reviewed) 
Excluded: 
- 37 Non-resource 
Meet Inclusion Criteria: 4 Limited Settings 
• 12 Lacking 
4 PubMed Qualitative 
Methods 
l To Oualitv Assessment I 
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For each of these 4 studies, I conducted a quality assessment based on the criteria as 
outlined in Table 2. Two studies were rated of good quality (Bikaako-Kajura eta/. and Abadia-
Barrero eta!.) while the two others were of fair or poor quality (Ellis eta/. and Makoae eta/.) 
The studies tended not to provide much, if any, justification for their use of qualitative methods. 
Also there was generally scant information on recruitment procedures of the subjects or the role 
of the researchers along with any potential sources of bias from interviewers or data collectors. 
However, the finding of 'red flags' was all together minimal, with the Bakaako-Kajura eta/. and 
Makoae eta/. studies having two red flags and Ellis eta/. having three. Because these criteria 
were a combination of qualitative methods quality assessments collected from other sources, 
their validity has not been reviewed by experts. Tables 3 and 4 outline the quality criteria each 
specific study met. 
a e . ua nv T bl 3 Q ft A ssessmen: 00 nena e tG dC't. Mt 
Recruitment Methods Roles of Findings 
Study Question Justifi· Criteria for procedures outlined Example researchers Confidenti· discussed explicitly Qualitative cation for a selecting and with of explicitly alityof Analytic with 
stated and design qualitative study declinations develop· methods stated and subjects approach reference 
justified described desiQn sample described ment Qiven biases addressed discussed literature 
Bikaako· 
Kajura, X X X X X X X X 
2006 
Abadia-
Barrera, X X X X X X X X X 
2005 
Ellis, 
2006 X X X X X 
Makoae, 
2008 X X X X X X X 
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T bl 4 Q f A a e . ua1ty tQ rtf SdRdFI ssessmen: ua1a 1ve IU1y e ags 
Researcher 
has multiple Recruitment of 
Study Simple roles, not consent ot ana!yzation, no No justification Findings Findings thoroughly Ethics of study study subjects 
complex theory or description anecdotal or generally full of discussed not well thinly 
generation of methods self-evident jargon or trite biases addressed discussed 
Bikaako-
Kajura, X X 
2006 
Abadia-
Barrera, X 
2005 
Ellis, 
2006 X X X 
Makoae, 
2008 X X 
Of the 4 studies found, only Bikaako-Kajura eta/. directly assessed ART adherence in 
children as their primary objective. Adherence was a secondary assessment in the other 
studies, or rather discussed within the context of a greater topic, such as with stigma or in the 
overall care of HIV positive children. Still, their findings yield some valuable information about 
ART adherence in children and allow us to better characterize potential barriers or facilitators. 
Also, two studies dealt with barriers to adherence from a caregiver's perspective only (Ellis eta/. 
and Makoae et a~. 
Bikaako-Kajura et a/.9 conducted in-depth interviews of 42 HIV-infected children taking 
ART and/or cotrimoxazole prophylaxis therapy (CPT) ages 5-17, and 42 primary caregivers, at a 
comprehensive HIV/AIDS clinic in Kampala, Uganda. Overall this study was of good quality, its 
major fault being absolutely no justification for using qualitative methods, or a discussion of what 
this type of method would add to our understanding, above and beyond quantitative studies, 
despite being a purely qualitative study. 
They developed an interview guide with semi-structured and open-ended questions that 
dealt with adherence to ART. They also asked questions regarding actual adherence rates. 
Though they gave us some information on the nature of their interview questions, few examples 
are given and we are left to speculate on the specific topics addressed in the interviews. 
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They found that strong parental-child relationships and disclosure of the HIV status to 
the child has a strong correlation to good ART and CPT adherence, and that not-disclosing or 
only partially disclosing made adherence more difficult. The younger the child, the stronger the 
parental relationship tended to be, which led to less resistance to taking the medications. As 
the children grew older, those who had not been disclosed to often became suspicious. The 
study defined this as 'partial-disclosure', where the child is suspicious and asks questions about 
his or her status, but has not been formally disclosed to. This tended to weaken the child-
caregiver relationship and there was much more resistance on the part of the child to take their 
medicine. Reasons for non-adherence such as side-effects, difficult regimen, or bad taste 
tended to become much more prevalent in this group. In other words, when the true purpose 
and benefits of the medications were not known, there appeared to be less motivation on the 
part of the child to adhere, which then made the job of the caregiver much more difficult. 
Forgetting was also more common among the non- and partial-disclosures, since the child had 
less motivation to help the caregiver to remember. ART adherence relies on a strong inter-
working relationship between the child and their caregiver. 
Irrespective of disclosure status, structural factors such as poverty and stigma were 
commonly cited as barriers to taking medicine. All other barriers assessed appeared to be 
secondary to the disclosure status. Children who knew their status were more likely to develop 
their own strategies to overcome these barriers, such as ways to remember taking their 
medicine and routines which avoided other people finding out about their status. 
Abadia-Barrero et af38 conducted an ethnographic assessment of 50 orphaned children 
living in Brazil. The authors measured the life trajectories of HIV positive children ages 1 
through 15 years. Data collection relied on standard ethnographic methodologies, which 
included participant observation and semi-structured, informal interviews. The primary focus 
was addressing the experience of stigma these children face and how accessing ART has 
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affected their experiences with stigma. Overall this study was of a good quality rating and met 
the highest number of criteria, as seen in Tables 3 and 4. 
Though the primary focus was not addressing adherence to ART, barriers to taking ART 
arose within the interviews. The main barrier to adherence appeared in the adolescents, who 
were almost solely responsible for taking their medications. Because they lived in a group 
home for orphans, they received much less adult care and supervision at this age than non-
orphans. This being the case, often it was a lack of understanding about the regimen that 
contributed to poor adherence. For instance, children had a poor understanding of the regimen 
and believed they could take their doses whenever they wanted throughout the day, which 
meant they were not adhering to the three times daily dosing typical among their regimens. 
Many of the children, who felt well, would purposefully not take their medications, as they did 
not understand why they should be taking medicine if they feel well. Often the children would 
simply forget to take their medicine without any kind of structure, or would prioritize personal 
enjoyment over taking a dose, such as continuing to play through a game of soccer. 
More open communication amongst all the children, and with the few adult caregivers, 
resulted in less adherence problems. It appears having some sort of support system in place, 
whether it be peers or adult caregivers, was important to maintaining good adherence levels. 
By grouping HIV positive children together in homes for orphans, issues with stigma and taking 
ART appeared to be less of an issue, which may be an important factor in ART adherence of 
orphaned children. 
Ellis et a/. 39 conducted a study to identify factors that predict adherence to drug 
regimens in Nairobi, Kenya. They recruited 357 adults to participate, however a subset of these 
were mothers who cared for HIV positive children (N=233). Both quantitative and qualitative 
methods were employed. Two quantitative surveys were developed to identify factors that 
predict adherence of drug regimens, while the second was developed solely for the subset of 
mothers regarding adherence in giving medicine to their children. They used focus groups as 
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their qualitative method, which were developed to farther probe answers from the quantitative 
surveys. 
Though this study had a 'poor' quality rating based on the qualitative study assessment 
scale, likely this is due to the fact the paper focused more on the quantitative methods and did 
not devote much of their text to describing their qualitative methods. None the less, we know 
little about study sample selected to undergo the focus groups, how and why participants were 
selected, how bias may have been addressed in a setting where information is shared with a 
group, or anything about the specific questions asked of these focus groups. Also, only some of 
the children were on HIV drug regimens. The study focused on drug regimens in general, so not 
all the findings may have been specific to ART. They do not distinguish which findings are 
specific to which type of drug regimen. 
The focus groups revealed that among the mothers who provided medication to their 
children, they found that lack of food, financial constraints, and timing of difficult regimens 
compromise the ability of mothers to adhere to their child's medication regimen. The mothers 
also report often simply forgetting to give the medication all together or having extreme difficulty 
in getting their child to take medication. The latter often occurs because of the large size and 
bitter taste of the pills. Further, when the child is resistant to take their medicine, the mother 
tends to report being unable to get the child to adhere as well over the long term. 
Most mothers agreed that their child's health is paramount to them and would rather 
supply the child with medicine than themselves, however they only travel to the doctor when 
absolutely necessary and often are delayed in seeking care. This hesitation may be due to the 
structural barriers which make it so difficult to travel to the clinics to receive refills and in some 
cases pay for their medications. These women tended to agree that they had faith in western 
medicine and that hesitation in seeking care or refills was not due in part by belief the pills were 
not helping. 
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Lastly, Makoae et a/.40 analyzed the challenges which caregivers encounter while 
providing care to HIV positive family members at home in Lesotho. Adherence to medication 
was addressed as part of their general care. The study enrolled 21 family caregivers to undergo 
in-depth qualitative interviews. Not all caregivers were in the care of children, some were also 
caring tor adults. The study does not provide characteristics of the study sample or to whom 
each caregiver provided their care. Therefore we do not know how many caregivers were 
caring tor children or the children's characteristics, but we are told in the findings that there is at 
least one mother, one father, and one grandmother who were caring tor children during the 
study. 
Findings are mostly reported as example quotations which highlight certain barriers to 
HIV care. Since the number of adults caring tor children is quite small in this study and no 
rigorous exploration of themes or qualitative analysis within this sub-group, the findings are 
mostly anecdotal with relation to medication adherence. Also, recruitment procedures are thinly 
discussed. Therefore this study received a 'fair' quality rating. 
The findings as they relate to ART adherence and children are minimal, though they 
produce a few findings. Barriers discussed mainly deal with cost and availability of medicine as 
an issue. These are not unique findings to this study. However, a more original topic discussed 
is that of the caregiver's health status and how disruptions in their health tend to negatively 
affect the care of their children. For instance, it a caregiver is ill such as with an acute illness, 
their ability to ensure adequate care, including receiving all medications, is compromised. In 
these cases, the child must be relied upon to some extent to take their own medication. Relying 
on other family members who may not know the proper medication regimens or even know the 
HIV status of the child can lead to poor adherence. 
These tour studies were all significantly different in scope, study design, and study 
population and it is difficult to produce a set of pooled results from all tour studies. The 
characteristics and findings of these studies are summarized in Table 5. 
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Table 5. Study Settinfi!. & Desifi!.n, Overall Qualiti:, Ratinfb and Summa;:r of Results 
Study Overall Barriers to Facilitators to Study Setting & Quality ART Adherence ART Adherence Design Rating 
Kampala, 0 Non-Disclosure of HIV status to 0 Strong parental-child 
Uganda the child relationship 
0 Financial constraints/poverty 0 Good communication 
Bikaako·Kajura, Qualitative Good 0 Stigma with HIV and taking between child and parent 20069 interviews with medications 0 Disclosure of HIV status to 
42 children 0 Other barriers secondary to Child 
and caregivers disclosure status 
Sao Paulo, 0 Lack of adults to supervise and 0 Living in an environment 
Brazil assist with the medicine with other HIV positive 
Abadia-Barrero, 0 Poor understanding of regimen children 
200538 Ethnographic Good 0 Feeling healthy 0 Support from other children 
study of 50 0 Poor communication with adult or adults 
orphaned supervisors 
children 
Nairobi, Kenya 0 Financial constraints/poverty 
0 Lack of food 
Ellis, Focus groups 0 Resistance from children due to 
200639 of mothers Poor difficulty of regimens or poor No facilitators reported 
who care for taste 
H IV positive 0 Difficulty with transportation 
children 
Lesotho 0 Financial constraints/poverty 
0 Difficulty with transportation; 
Makoae, Qualitative availability of medicine 
200840 interviews of Fair 0 Poor health status of caregiver No facilitators reported 
caregivers with 
HIV positive 
children 
Discussion: 
This systematic review presents the first comprehensive review of the qualitative 
methodology used to better understand pediatric ART adherence in resource limited settings. It 
is immediately evident that there is a paucity of this type of research, which supports this 
assertion noted in a number of other articles. 16• 29 Because these studies use heterogeneous 
methods and study populations, it is difficult to draw broad conclusions or to generalize findings 
based on all four studies. However when looking at the results as a whole, common themes 
that arose within these studies were those of structural barriers (financial constraints and 
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transportation) as well as situations where the caregiver is impaired, or not present, for 
motivating or assisting the child to properly take their medications. Also, conflict between the 
caregiver and child appears to serve as a barrier to good adherence. 
The quality and breadth of information obtained from the Bikaako-Kajura eta/. study9 was 
much more in depth than the other three studies and was most valuable to the understanding of 
this topic in resource limited settings. Their primary objective was assessing pediatric ART 
adherence, where as the other three studies only address ART adherence with in the context of 
larger objectives such as dealing with stigma, medication adherence relating to all medications, or 
with overall care of HIV positive individuals. Therefore the results from the other three studies do 
not have as much significance to this review and typically their findings were more anecdotal 
since there were fewer subjects speaking on ART adherence with which to draw conclusions. 
Significant, and well explored, in the Bikaako-Kajura eta/. study was the issue of non-
disclosure and its effects on adherence. The underlying theme was conflict created between 
the child and parent due to this issue. Many of the children in this study were suspicious of their 
HIV status and were considered 'partially disclosed', meaning they may have had some idea 
about their status, but no one had confirmed it specifically. This created an atmosphere of 
tension and lack of trust between the child, caregiver, and clinical staff, especially for older 
children or those nearing adolescence. Without a strong rational behind taking such medications, 
there is little motivation on behalf of the child to do so. The findings in the Abadia-Barrero eta/. 
study seem to support Bikaako-Kajura eta/., where they note poor communication with the child 
and lack of a strong caregiver-child relationship seemed to create conflict, lack of motivation, 
and adversely impact ART adherence. 
Judging from these studies, it is clear maintaining good adherence was difficult for many 
children and some sort of adherence strategy is needed. This strategy may need be unique to 
each child, however employing both the child and a caregiver into a given strategy is the most 
effective means of doing so. Without a partnership, adherence entirely depends on the 
29 
caregiver support strategy, availability, and willingness to give medicine as prescribed, which is 
much more difficult as a long term strategy. The common facilitator noted between Bikaako-
Kajura eta/. and Abadia-Barrero eta/. studies was that of providing a support system to the 
child. This could be having other HIV positive children to rely on for support, or having an adult 
caregiver with whom there is a relationship of trust. 
Three of the four studies noted structural barriers as significant barriers to good 
adherence. This is not surprising, as previous reviews looking at children in some developed 
settings and adult populations in resource limited settings have also found that structural 
barriers such as financial constraints, access to medications, and transportation are significantly 
associated with maintaining good adherence.16• 29 The difficult question is how to address and 
overcome these structural barriers in resource limited settings, which can be extreme for both 
children and adults. 
This systematic review suggests that the need for strategies to overcome child-caregiver 
relationship and structural barriers is paramount. Training social workers or support staff at 
clinics which provide ART may be effective in helping children and caregivers to develop coping 
strategies for structural barriers. This could employ techniques such as Motivational 
Interviewing, which have been used to promote adherence in developed settings.27 Formation 
of child peer support groups for behavioral reinforcements may also be useful. This strategy 
may only be available to children who know their HIV status, however peer support groups for 
adult caregivers of children who do not know their status may be a useful alternative. 
For children who do not know their status, Bikaako-Kajura eta!. 9 recommend 
counseling to discuss the nature of the caregiver-child relationship, relational barriers, and ways 
this can be improved, without necessarily having to address their ART regimen or HIV itself. A 
better overall relationship may translate into better communication regarding their medication 
regimens. Children who ask many questions about their drug regimen or with suspicions about 
their status may need special attention. There may be specific psycho-social issues regarding 
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this sub-set of children and specific mechanisms of support should be available at the ART 
clinics for both the caregiver and child. 
Ultimately, caregivers should be encouraged to disclose the HIV status to the child. This 
is also not easy for those living in settings where the stigma associated with the disease is great 
and other family members may also be unaware of the child's status. However, despite these 
problems, previous studies show that children generally want to know their status and it appears 
this could facilitate better ART adherence.21 
This review has a number of important strengths. The methods employed to tabulate 
these findings come from a multi-step process which is clearly outlined in Figure 2. A number of 
different search strategies were employed with the aid of librarians who were very familiar with 
the databases and trained to determine which strategy would carry the best balance of 
sensitivity, yet still keeping a narrow enough focus of the topic. 
Pooling the results seemed infeasible due to the heterogeneity of methods. Because 
there were few studies, this seemed largely unnecessary as well, with only four studies meeting 
inclusion criteria. While a number of themes arose among the studies, they can be easily 
surmised in Table 5. Though the quality criterion has not been validated, it is taken from a 
number of sources which assess the quality of qualitative research. Since I found a range of 
good, fair, and poor quality studies, it is reasonable to believe this criterion is capable in 
discerning between well done studies and those whose methods are lacking. 
I do acknowledge the number of studies found with this method is quite small. Whether 
a more robust search strategy exists or a rnore in-depth search of additional databases or 
abstract searches would have yielded more studies is unknown. However I believe this is 
unlikely, as systematic reviews which have looked at this topic in developing settings have 
found the same paucity of qualitative studies. One previous review frorn 2006 found only 37 
studies ever using qualitative methodology, in any setting, dealing with both adults and children 
and assessing ART adherence.29 Narrowing down to children only, there were a mere 8 
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studies conducted in developed settings. Indeed, the fact that even four studies were found in 
resource limited settings that dealt with this topic is somewhat surprising. 
Other limitations to this review should be acknowledged. Because this review has only 
one author, there was no way to validate the review process or selection of studies to assess for 
agreement. Only studies in English and French were considered, though no studies in French 
were found. It is still possible some relevant studies in other languages may have been 
overlooked. Publication bias could potentially be a concern. However since qualitative studies 
typically represent formative research, I believe it is unlikely that some qualitative findings would 
selectively remain unpublished. Further, two of the four studies did not have ideal 
methodological strength and their findings may not have great significance for this reason. It 
may also be incorrect to assume findings from one resource limited country to another will be 
applicable. There is great breadth between populations in these countries. The children of 
Brazil may face a very different reality from those of Uganda or Lesotho when taking their HIV 
medicines. 
More high quality studies are needed from different resource limited settings to better 
understand the barriers and facilitators of ART adherence in children. Development of an 
improved theory and best practice guidelines for pediatric ART adherence are severely needed. 
Also, more quantitative studies that employ culturally appropriate models to accurately measure 
adherence and a better established definition of what ' good adherence' means with regards to 
children in resource limited settings are warranted. 
Future qualitative research in this area will have a number of questions to answer. It will 
be important to determine if indeed the disclosure status of the child plays a strong role in 
maintaining good adherence in other settings, aside from the Bikaako-Kajura eta!. study. The 
perspective of the caregiver will especially be important to assess, since the adherence of the 
medications depends heavily on them. How do these caregivers approach maintenance of 
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good adherence in non-disclosed children? How are strategies different, and perhaps more 
successful, with caregivers of disclosed children? 
Though we know that structural, cultural, and social barriers can make ART adherence 
difficult in children, understanding the 'why' behind these barriers will be helpful to developing 
strategies to overcome them. Along these lines, we also need more information on facilitators 
to good ART adherence and a better understanding on why certain practices or strategies tend 
to aid in adherence. The studies in this review did not focus on identifying and exploring 
facilitators, though facilitators were briefly mentioned in two of the studies. 
As found in prior reviews, qualitative studies are superior at identifying and 
understanding patient-important barriers and facilitators and should set the basis for future 
quantitative works. 29 More studies will be useful to support and add to the findings of these four 
studies, and to determine whether barriers and facilitators in one resource limited setting are 
similar to others. Though three of the four studies found in this review were performed in Sub-
Saharan Africa, more are needed in this region, where 90% of pediatric HIV cases exist and 
scale-up of ART access to children continues. 
None of the studies provided information about the length of time children had been 
prescribed ART, so it is difficult to make comparisons between the children with-in, or between, 
studies. It is also likely adherence practices change over time, especially when illness improves 
or side-effects increase. Future studies may make better measure of the time frame of the ART 
regimens they are assessing and correlate this as a barrier or facilitator to good adherence. 
This review identified a range of barriers and facilitators of adherence for children taking 
ART in resource limited settings. Though certainly not comprehensive, this information can 
serve as a guide for future interventional research to improve adherence rates. Clinicians or 
support staff practicing in resource limited settings can use this information to engage in open 
discussion with patients, promote adherence, and even identify barriers and facilitators in their 
own population. 
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ART adherence is crucial to maintaining the health of HIV positive populations. Though 
good adherence may become easier over time with simplified regimens and increased cultural 
acceptance and understanding of HIV, maintaining good adherence and measuring this 
adherence in resource limited settings will continue to provide challenges. Additional research 
geared towards children will shed light on best clinical practices and bring the focused attention 
necessary on this area required to address it. 
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Ill. Research Plan 
1. Overview and Rationale 
Background: 
The Democratic Republic of the Congo (DRC) is a war torn nation of around 63 million 
inhabitants.41 Since 1998, on-going conflict in the eastern part of the country has been 
characterized by extreme violence, mass population displacements, widespread rape, and a 
collapse of public health services.42 This has been dubbed 'Africa's first World War' due to the 
number of nations involved and population affected. To date, nearly 4 million people have been 
killed as a result of the unrest, the highest number in any conflict since World War 11.42 In recent 
years, the violence has ebbed somewhat due to the signing of peace accords by various 
factions and the presence of UN peacekeeping troops. However outbreaks of violence in the 
eastern part of the country are still common. 
The DRC (formerly Zaire) was one of the first countries to develop and HIV/AIDS 
prevention program in the 1980's. Due to the political, social and economic impacts of conflict 
during the 1990's, this region unfortunately now lags behind many other African nations in the 
development of a stable public health infrastructure. This means that continued progress in HIV 
prevention and treatment, among many diseases, has been slow. The capital city of Kinshasa 
in the western part of the country has fortunately received relative stability in recent years and 
some progress has been made in terms of addressing the HIV epidemic. 
In November of 2004 the Sustainable Antiretroviral Access (SARA) Program was 
initiated at several of the public hospitals in Kinshasa. This program is a collaboration between 
the University of North Carolina- Chapel Hill and the Kinshasa School of Public Health. Their 
goal was to provide antiretroviral therapy to both HIV positive children and adults within the 
Kinshasa region and to assess the feasibility of such an undertaking. 
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Despite the fact that one of the earliest known strains of HIV was detected in the 
Kinshasa region dating from 1959,43 the DRC has remained on the low end of HIV prevalence 
rates, relative to sub-Saharan Africa. Data from 2007 estimates the HIV prevalence range on 
the order of 400,000 to 500,000 cases.41 37,000 to 52,000 of these cases are estimated to be 
in children less than 15 years of age. These numbers put the countrywide prevalence at a rate 
of around 1.2-1.5%. However, sentinel site surveillance in pregnant women suggests that the 
prevalence is higher in urban settings. A 2004 survey revealed HIV prevalence to be around 
4% in Kinshasa and as high as 7-9% in other urban settings.41 • 44 The accuracy of this HIV 
prevalence data is difficult to ascertain. In a war torn region such as the DRC, it is possible 
these numbers are under reported since accurate data measurement is difficult in many areas 
of the country. Other estimates of HIV prevalence put the total number of people living with HIV 
upwards of 3 million.44 
It is clear that provision of ART has also lagged behind in the DRC and is limited in many 
provinces. Though the prevalence may be low relative to other sub-Saharan African countries, 
those with HIV typically do not receive adequate care. The country is large, has a sizeable 
mobile population, and health care services are inadequately decentralized. There is a severe 
shortage of human resources trained to deliver antiretroviral therapy.44 Of those HIV positive 
individuals in need, only 20% to 29% were estimated to be receiving ART, most of whom live in 
Kinshasa. 41 Only 1,632 HIV positive children are recorded as receiving ART, which is a mere 
3.1% to 4.4% of all HIV positive children in the country.' 
The SARA Program has begun to address the need for HIV treatment in Kinshasa, 
especially with regards to children. As of September 2008, the SARA program served 737 HIV 
positive children <18 years of age, 503 of which were started on ART. The recommended first-
line drug regimens are stavudine + lamivudine + nevi rapine or stavudine + lamivudine + 
efavirenz.44 The average cost of first-line treatment is about $348 (USD) per person per year. 
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Overall, more study is needed on nearly all aspects of HIV prevention and treatment in 
the DRC. Years of civil unrest have damaged the health care delivery system and the ability to 
successfully perform research in many areas of the country is compromised.44 Much of the 
research done in other areas of sub-Saharan Africa may be generalizable to the DRC, but not 
all. This is especially true with subjects that may address culturally specific behavioral or social 
issues, such as adherence to ART. 
ART Adherence in Kinshasa: 
Access to ART has lagged behind for children all across sub-Saharan Africa. As 
mentioned, the DRC appears to be no exception. Data on adherence to ART in the DRC is not 
surprisingly sparse, considering the relatively small number of children currently taking ART 
regimens. 
Some preliminary data on adherence does exist from children receiving care at the 
Kalembe Lembe Pediatric Hospital (KLL) in Kinshasa, collected through the SARA program. The 
data comes from provider administered questionnaires to both caregivers accompanying children 
at clinic visits and from children themselves, who are over 12 years of age. 
This data reveals >99% of caregivers and children > 12 years of age are reporting 100% 
adherence within the last 2 days along with zero days of missed treatment within the last month.45 
This is well above expected norms of children in similar settings, where favorable adherence rates 
range from 50% to 80%.16 These data also lack the expected variability in adherence rates 
between subjects and the figures are likely inaccurate. Failure rates of ART have not been well 
recorded in children at the KLL Pediatric Hospital. However, failure rates of first line ART 
regimens in children are increasing in number and have been shown to be twice as high as adults 
in similar settings.46 
It is known that provider administered questionnaires are vulnerable to a social desirability 
bias and can lead to inflated figures on ART adherence. As mentioned in Section I, this method is 
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not optimal for measuring adherence and the SARA adherence rate data is likely over inflated, 
however it is difficult to estimate the degree of this. 
Study Rationale 
Pediatric adherence to ART has not been widely assessed in sub-Saharan Africa, where 
over 90% of children living with HIV are located.9 Because the number of children accessing 
ART is rising substantially each year, best practice guidelines to ensure high rates of adherence 
is needed. Without an in-depth understanding of what makes these regimens more difficult, or 
perhaps easier, in sub-Saharan Africa and other resource limited settings, these best practice 
guidelines will be difficult to synthesize. 
Since little data exists on adherence to pediatric ART regimens in Kinshasa and in 
resource limited settings in general, the Kalembe Lembe Pediatric Hospital represents a prime 
target for farther study. I am proposing a study which assesses barriers and facilitators of 
adherence to ART regimens in children through qualitative, formative research. 
Qualitative methods represent a practical place to begin study in this setting. This type of 
methodology can be used to inform the development of more valid, culturally appropriate 
adherence measures and a contextual adherence theory and can serve as validation to any future 
quantitative studies addressing adherence in Kinshasa. 16 As described in Section II, very few 
qualitative studies assessing pediatric ART adherence in resource limited settings exist, and even 
fewer are generalizable to the context of Kinshasa. 
2. Research Plan Procedures & Methods 
Setting: 
The SARA program is a longitudinal, prospective cohort of comprehensive HIV care and 
management, including ARV treatment, for adults and children in Kinshasa, DRC. The program 
operates at several public hospitals and clinics in Kinshasa. All enrolled subjects receive 
primary HIV care, including management of opportunistic infections and psychosocial support. 
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Subjects who meet specific criteria are also started on ARV treatment. For children, this 
includes being HIV positive, aged 0 through 17 years, who had been receiving HIV/AIDS care 
before the start of the program or who were identified HIV positive through the expanded HIV 
testing strategy (op-out system) at the KLL Infectious Disease Unit. Children under 18 months 
with confirmed HIV infection with a positive viral test result are also eligible to participate in the 
SARA program. All participants in this study will be recruited from the subset of children 
receiving ART within the SARA Program at the KLL Pediatric Hospital in Kinshasa. 
Subjects, Recruitment. & Consent: 
During a six week period over May and June 2009, we will recruit approximately 40 
study participants for qualitative in-depth interviews. These participants will be children 8 years 
of age or older who are actively receiving regimens of ART, enrolled in the SARA program, and 
receiving care from KLL physicians and staff. We will also recruit the adult who accompanies 
the children to their regularly scheduled clinic visits. If more than one adult accompanies the 
child, we will recruit the one who has the most active role in caring for the child. We will also 
recruit caregivers with young children below the age of 8 to participate. Specific inclusion and 
exclusion criteria are outlined in Table 6. 
Participants will be selected from the daily SARA appointment list at the KLL HIV clinic. The 
psycho-social support staff at KLL, typically trained social workers, will approach caregivers which 
meet inclusion criteria after they have completed their daily clinic visit. They will be asked to remain 
in their clinic room by the clinic staff so they can be approached in a private manner. The qualitative 
interviewer, who is fluent in Lingala and French, will approach the caregiver and tell them we are 
interested in asking some questions about themselves and their child for a study that UNC-Kinshasa 
School of Public Health and the clinic are performing. We will not mention anything about medications, 
HIV, other illnesses, or of the exact nature of the interview questions at that time. We will explain that 
we would like to sit down and interview them in a separate private room by themselves, overview the 
time it will take, and that there will be compensation for completing interviews. 
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If they agree, we will take the caregiver to the private, closed off room in the clinic where the 
consent forms will be provided and the study objectives described in greater detail, as per the script in 
the attached Interview script and questions. If they refuse to participate, reasoning will be 
documented if given. During the interview, the child (and other accompanying children) will remain in 
the care of the clinic staff or other research personnel. The caregiver will be informed that they may 
opt out at any point during the process without penalty and compensation will still be provided for their 
time given. 
If consent is given for children over the age of 8 to participate in the study, the qualitative 
interviewers will interview them in the same private room alone, after completion of the caregiver 
interview. Their caregiver will be asked to remain in the clinic waiting area. 
For recruitment purposes, a history of non-adherence will be elicited in two ways. First, 
selection will come from previous medical records, which the clinic staff will review prior to the clinic 
visit for documentation or suspicion of non-adherence to ART. Since we will be working in close 
collaboration with the clinic staff, we will also elicit non-adherence from clinical suspicion during or 
immediately following the scheduled appointment. The physicians, nurses and psychosocial support 
workers will be instructed to alert study personnel if this is the case. 
If selected from medical records, the definition of non-adherence will be documented based 
on the written record. If selected based on clinical suspicion, the physicians and/or psycho-social 
support workers will be asked to explain their reasoning (i.e. admitted non-adherence, unusual failure 
of first line therapy, falling viral load or CD4 count, continued poor clinical presentation) 
We will attempt select 1 to 2 patients (a child and their caregiver) per day for interviews over a 
2 month period, beginning in May of 2009 and running through July 2009. We will attempt to recruit 
an equal number of male and females, different ages, disclosed and non-disclosed, as well as some 
caregivers who care for children below 8 years of age. However, we may be limited by selecting for 
patients with a history of non-adherence. Because final examinations are occurring for school 
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children during this time, we may also invite adult caregivers and their child to return on Saturdays for 
the interviews. 
Typically, qualitative interviewing is an iterative process. It continues until a set of 
themes on particular topics begin to arise and reach saturation. Previous studies on ART 
adherence have reached saturation of themes with anywhere from 20 to 50 participants.9• 32• 40• 47 
Therefore we will conduct as many interviews as feasible within this time frame, which we 
anticipate will be anywhere from 30 to 50 adult caregivers and children. 
Table 6: Inclusion & Exclusion Criteria 
Participant 
Children 
Adults 
Children & 
Adults 
Criteria 
Inclusion: 
(1) Aged 8 to 17 years and enrolled in the SARA program 
(2) Actively receiving care at KLL for at least 6 months 
(3) Have been prescribed and actively taking an ART regimen for at least 6 
months 
(4) Have a documented history of poor adherence noted within their medical 
record or a clinical suspicion of non-adherence supported by the physicians, 
nurses, or psychosocial support staff at KLL at the time of the clinic visit. 
(5) Must speak French or Lingala 
(6) Willingness to be interviewed alone 
Inclusion: 
(1) At least 18 years of age or older 
(2) Accompanying a child aged 6 months to 17 years to their scheduled clinic 
visit 
(3) Must have known the child for a minimum of 6 months (if not a primary 
relative) 
(4) Must speak French or Lingala 
(5) Willingness to be interviewed alone 
(6) The child they accompany must have a documented history of poor 
adherence noted within their medical record, or a clinical suspicion of non-
adherence supported by the physicians, nurses, or psychosocial support staff 
at KLL at the time of the clinic visit. 
(7) The adult care giver is aware of the child' HIV status 
old 
Exclusion: 
(1) Adult and child (if 8 years of age or older) are unwilling to be separated for 
interviews 
(2) Both adult and child do not speak either French or Lingala 
(3) The participant is personally known to the qualitative interviewer or other 
study personnel 
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Qualitative Interviews: 
The interviews will assess the opinions and experiences of the study participants in 
dealing with ART regimens. General themes explored with adult caregivers will include overall 
attitudes towards ART regimens, perceived benefits or liabilities of ART, health beliefs on ART 
and on HIV, what good adherence means to them, perceived barriers in carrying out regimens 
as prescribed, facilitators which aid ART adherence, and an assessment of the child's specific 
adherence rate. With the children, we will explore similar themes. These include beliefs 
regarding ART and HIV as well as what they perceive to be barriers and facilitators to good 
adherence. Throughout the process, we will explore specific instances of missed doses. 
Trained qualitative interviewers who are fluent in French and Lingala, the local language, 
will carry out all recruitment procedures and conduct interviews, under the supervision of the 
study coordinator and clinic staff. These interviewers will follow scripts that have a list of themes 
and corresponding questions with probes to be addressed with the study participants. The 
interview script can be seen in Addendum I. Questions were based on prior literature searches 
which explored potential barriers to ART adherence. The semi-structured nature of the 
interviews and multiple question probes will allow the interviewers to explore topics in detail 
which are relevant to each participant. This flexibility will allow us to explore and clarify 
emerging issues pertinent to ART adherence as they arise. 
There will be a day of orientation to the study for the qualitative interviewers and clinic 
staff, before recruitment begins, explaining the study protocol for adults, children who have had 
HIV status disclosure, and children who are HIV status na'ive. There will be several practice 
runs through the study protocol with study personnel, the clinic staff, and the qualitative 
interviewers that will serve as pre-testing. The study team will comb through, in-depth, the 
recruitment procedure, the consent process, and each of the three interview types (adults, 
status disclosed child, and non-disclosed child) for potential problems and areas for 
improvement. 
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The qualitative interviewers will have received previous training on qualitative interview 
techniques and research methods. Recruitment procedures are farther outlined in the Standard 
Operating Procedures in Addendum II. Interviews will be carried as per the interview script and 
question forms, attached submitted as the Interview Script Form. The interview script and 
questions will be translated into French and Lingala with the aid of translators and input from the 
clinic staff. 
Participants will be taken to a private, closed off room within the hospital for the consent 
process and the interviews. The initial interview script will serve to introduce the study and to 
de-stigmatize the issue of non-adherence. Some information on the caregiver and their 
relationship with the child will be ascertained from an initial questionnaire administered after the 
initial script but before the qualitative interview questions begin. Interviews will last anywhere 
between 30 to 120 minutes for the caregivers and 30 to 90 minutes for the children and they will 
be recorded by a digital sound recorder. 
Keeping interest and engagement of some of the younger children will be challenging, 
so interviews will end early if the child no longer remains focused and can no longer be engaged 
despite several attempts. Caregivers and children will be interviewed separately. Children will 
be supervised by research assistants while the caregiver interview takes place. If the child is 
younger than 5 years of age, he or she may stay with the caregiver during the interview, if the 
caregiver wishes, though we will encourage solo interviews. If the caregiver and child (5 years 
or older) do not wish to be separated, we will not conduct the interview, as the presence of one 
another may bias the responses. 
For children who have not been informed of their HIV status and do not know the true 
nature of their medications, we will use a separate interview script It will be important to address 
the difficulties these children face with their regimens without alluding to the true nature of their 
medications or that they may have any specific type of disease or condition. 
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Interviews will be transcribed from the interview audio files and entered into Microsoft 
Word (Redmond, WA). During this process, they will be translated into English directly from 
Lingala. Also, demographic information, data from Section I of the interview script and questions 
'zero' from both child interviews will be entered in to a Microsoft Excel database for storage. 
These files will be brought back to the US for analysis. Used interview script forms and consent 
forms will remain in Kinshasa for record keeping purposes and storage. 
Benefits and Risks to Participants and Safety Measures: 
There may be no immediate direct benefit to the individual study participants, other than 
an increased awareness of the specific challenges each caregiver and child faces in 
administering ART regimens. However, increased introspection and identification of barriers 
may potentially serve to reduce and overcome such barriers. 
The findings of this study will serve to aid the SARA Program staff at KLL, and others 
who provide pediatric HIV treatment in resource limited settings, to better understand why 
caregivers have trouble administering ART to their children and why children may not always 
take all of their medications. 
Virtually all research studies carry inherent risks to personal privacy, and this study will 
be no exception. This includes the possibility that personal or private medical information may 
be inadvertently divulged to non-research personnel. Specifically, divulgence of the HIV status 
of the caregiver or child may cause difficulties within the participants' community if inadvertently 
disclosed to other people in their community. This may cause emotional distress, 
embarrassment, and a feeling of mistrust towards the clinic and towards participation medical 
research. 
Qualitative interviewers and staff may have access to identifying information. However, 
they have had training in research methods and in keeping the confidentiality of research 
subjects. They adhere to the research practice standard set forth by UNC and the SARA 
Program. 
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We will take every precaution to ensure that identities of the study participants remain 
blinded to all study personnel and that recruitment procedures do not divulge any information 
regarding the study until located in a private location. At the beginning of the interview, post-
consent, each participant will be assigned a study identification number by the PI (ie. 
A(Adult)#007 or C(Child)#007). All study forms and audio tapes will identify participants only by 
this assigned study ID number. Participant names will not appear on any forms or the audio 
tapes. Their identities will be linked with their ID numbers in a separate MS Excel file. This will 
be a password protected file and will be stored with study personnel in Kinshasa. This file will 
be destroyed after completion of the study analysis. 
Disclosure of HIV status to naive children is a serious concern. Children who have not 
been disclosed of their HIV status, or have only partially been disclosed, have been shown to 
have worse adherence rates when compared to children who have been disclosed of their 
status.9 Therefore, information collected from these children will be extremely valuable to the 
study, as they may share a very different perspective on taking their medications than children 
who know their HIV status. Every precaution will be taken to assent and interview these 
subjects in a manner in which does not divulge the nature of their medications or their relation to 
any specific condition or disease. 
The interview script for non-disclosed children does not refer to HIV, the purpose of their 
medications, or that their medicine may be for a specific cause at all. However, we cannot 
ensure that interviewing these children will not raise their suspicion or result in an increased 
interest in the true nature of their medication regimens. There is potential for psychosocial harm 
to the child if their status is inadvertently divulged or discovered before their caregiver has 
deemed them ready, as well as caregiver anger and a feeling of misplaced trust in our research 
practices. The caregiver will be informed of these risks prior to consent and be allowed to view 
the questions that will be asked of their child. 
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Consent forms will be provided to adults for their participation and adults for their child's 
participation. These will outline the purposes of the study and pertinent risks and benefits for 
participation. The U.S. Department of Health and Human Services suggests assent should be 
sought from children aged 13 and older (Department of Health and Human Services (DHHS), 
2001) so assent will be obtained from adolescents aged 13- 17 years of age. The forms will 
require a signature. If the participants cannot read or wish not to read it themselves, the 
interviewer will read the forms out loud and can sign with a stamped fingerprint. 
Compensation to Participants 
Sub-study participants will be compensated for their time at a rate comparable for 
payment of citizens' time in Kinshasa, Democratic Republic of the Congo. Caregivers will be 
compensated $5 (or equivalent Congolese Franc amount) for completion of a full interview and 
an additional $5 for their child's time, if they are eligible and participate in the study. 
Compensation will occur at the end of the interviews in the confines of the private room. Snacks 
and beverages will also be provided to both adult and child participants at the beginning of the 
interviews and throughout, as per interview script. 
Analysis of Data 
Qualitative data will be entered into software that aids in qualitative data analysis and 
analyzed. With the aid of these programs, codes will be assigned to conceptual patterns or 
themes which arise in the interviews. At least two study personnel will work through this 
process until a consensus of these patterns or themes are reached. We will draw conclusions 
on barriers and facilitators to ART adherence based on these patterns or themes and the 
characteristics of the adults and children to whom they apply. 
We will also collect some demographic data on each study participant. This data will 
come from the first section of the interview script and will be used to quantitatively describe the 
characteristics of the study population. Analysis of data will occur during the months following 
completion of the interviews. 
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IRB Application 
Approval for study was acquired from the University of North Carolina internal Review 
Board (IRB) on April27'h, 2009 and from the Kinshasa Ethics Review Committee on June s'h, 
2009. The Standard Operating Procedure, detailing the study protocol as outlined in the IRB 
application, can be seen in Addendum II. This study will ultimately be reviewed for possible 
publication once the analysis is complete. 
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IV. Implementation of Research Plan and Lessons Learned 
Feasibility of the Research Plan 
Throughout the course of six weeks in Kinshasa, Democratic Republic of the Congo, I 
was able to implement the research plan and gauge the feasibility of performing this study, and 
qualitative research in general, in a resource limited setting. Overall I found that with the correct 
resources and preparation, a study implementing qualitative interviews or other qualitative 
methodology is quite feasible and can yield meaningful results. 
The key aspect to performing qualitative research is a significant understanding of the 
society and culture of those subjects who are solicited for participation in such studies. 
Because these types of studies involve direct interaction with locals, it is imperative that the 
protocol take into account cultural norms. For instance, when dealing with a subject such as 
ART adherence, it was extremely important to know that Congolese people are typically polite in 
such a way they will almost always tell you what they think you want to hear. Therefore we had 
to make extra care in explaining to the research participants that we wanted their true opinion, 
not simply what they thought was the 'right' thing to say. 
It was important that the majority of the study team were local Congolese. This was 
especially true of the interviewers and participant recruiters. It would be impossible for 
foreigners to travel to this setting and perform these interviews themselves, and without bias, 
since they would inevitably lack an understanding of the mannerisms of a culture that come 
from being raised and living within it. Having the study team look over the methods of the study, 
namely the interview questions themselves, was also important to ensure these questions were 
culturally relevant and would make sense to participants. For instance, one question asked 
about their thoughts on how society's attitudes made it difficult to adhere to their medicines. 
However, 'society' could be construed in many different ways to a Congolese and we needed to 
be much more specific and provide examples about what the question meant. Further, when 
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asking about facilitators, questions regarding the improvement of motivation were to be asked, 
however there was no direct translation of the word 'motivation' into Lingala and the question 
needed to be reworded to accurately obtain the desired information. 
It's also important to respect and understand the different cultural values associated with 
medical care and certain diseases, such as HIV. It can be challenging for patients to open up 
about HIV, even to the medical staff to whom they are familiar with. Throughout sub-Saharan 
Africa, this topic has typically been regarded as taboo and can be a form of 'social suicide' in 
some situations to admit yourself or a family member as HIV positive. It was extremely 
important to make clear to the participants that the interviewers were an extension of the 
medical staff at KLL hospital, and that the same strict standards of confidentiality applied to 
them, and to all of the study staff, as well. Without this understanding, we likely would not have 
received open and honest answers about their HIV medication regimens. 
Probably the most challenging barrier of the study was addressing the safety of children 
who were not disclosed of their HIV status. This turned out to be a major barrier in caregivers 
allowing their children to participate. Therefore we had to make extra clear and give extra effort 
in allowing the caregivers to understand exactly what would happen during their child's interview 
and that our study team was very cognizant of this issue. Simply glazing over the issue with the 
caregiver and covering it quickly was not sufficient. We needed to pause at this issue and make 
sure the caregivers were comfortable and had time to receive assurance and have questions 
answered. Otherwise we risked a reflex refusal from the caregivers to let their child to 
participate when prompted, as if it were too complicated or risky to even consider. Throughout 
our first day of interviews, we had time to adjust to this and improve our ability of communicating 
on this issue. 
Local staff had to be hired to carry out the study. The only disadvantage to this in the 
realm of qualitative methods is the hiring of a staff that is well trained in this type methodology. 
Whether this is interviews or focus groups, it takes some significant training and experience to 
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properly carry them out. With the aid of the UNC-DRC staff and my own personal preparation, I 
was able to conduct training of these interviewers. Fortunately our staff had already been 
trained before. However, we developed a refresher session on conducting qualitative interviews 
so that they may be well aware of certain pitfalls of asking about ART adherence. 
During the training we mainly focused on qualitative interviewing techniques and 
concepts important to obtaining the highest quality possible information in dealing with 
medication adherence. This included addressing topics like leading the interviewees or 
introducing bias into their responses by the way the ask questions and probe. Because many of 
the interview questions were open-ended or semi-structured, and had many probes, the 
interview process was a key focus. This was especially important in working with a topic, such 
as medication adherence, where patients will often want to tell you what you think you want to 
hear. Also, working with children and getting them to open up can be particularly challenging, 
so communicating and practicing patience was important for those interviewers who had not 
worked with children before. 
Overall, with strong local input for pre-testing research methods and protocol, an 
adequately trained study team, and an in-depth understanding of the culture you are working 
with, such studies are quite feasible and can yield highly valuable information. Communicating 
with local colleagues and having a research infrastructure already in place made this possible. 
However there were many other general lessons to be learned in preparation for an 
international research project. 
Lessons Learned in Conducting International Research 
Conducting a study in an international setting can be very challenging. Language, 
cultural, and social barriers can be significant. Also, the resources available in one setting may 
be completely different than what's available in more familiar settings, such as the USA. If 
developing a plan to work in a particular resource limited setting, one should take the time to 
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perform significant research about the place and its people in order to develop a study which is 
both feasible and valuable for the local population. 
Language was the most significant barrier for my participation in international research 
and should be a primary consideration when working in a foreign setting. Communication is key, 
and if you cannot communicate effectively it will be impossible to conduct research efficiently. 
One must successfully communicate with both the study staff and research participants. 
Fluency in the native language is highly recommended. Though not fully fluent in French, with 
some effort I felt I was able to engage with my colleagues, communicate each other's needs, 
and facilitate the research project as successfully as possible. This however took much effort 
and the availability of an English-French translator. It is also possible the research subjects will 
speak different languages. In many settings there can be a number of indigenous languages, 
so preparation for a study should take this into account. 
Before developing a research plan for a particular setting, one must 'do their homework'. 
It is important to have an understanding of the environment. Who are the population and what 
resources will be available? What are the community's needs? Will a particular project really 
be useful to the people living in the setting? If so, one must approach working in a new setting 
with respect. For instance, the typical method to go about achieving an objective or 
accomplishing a task may be different. You cannot expect people to work as you would in your 
home environment. Deadlines and meeting times may be much more flexible in certain settings, 
so one must be patient and able to go with the natural flow, or risk alienating foreign colleagues. 
My own personal experience found that more advance planning was needed. Ideally, 
project planning should not be rushed, as many important things can be overlooked. However, 
in the real world this must be balanced with deadlines and our own personal time constraints. 
Namely, my planning issues dealt with budgeting and scheduling, which needed more work 
before beginning the implementation phase of the project itself and traveling to Kinshasa. 
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Some unexpected issues were likely unavoidable. However, seemingly basic supplies in 
this particular setting were quite expensive and fitting the project into my budget was difficult. 
This may have been better researched before traveling to an international setting. Also, Ethics 
Committee meetings were not as regular or standardized as with my experiences in the USA, so 
this process took rnuch longer than anticipated and the project was delayed. Time can run 
much slower in these settings and expect that less can be accomplished in a given time frame 
when working in an unfamiliar setting. 
These experiences have helped me to better understand how to go about research in a 
resource limited setting and what type of future expectations I should have when moving 
forward with future research. Overall, implementing research at the UNC-DRC facility and KLL 
was challenging, but rewarding. The research plan was flexible enough to where it could 
successfully be implemented. However, without large amounts of determination and patience 
on my part, and the knowledge and aid of others in Kinshasa, it would not have been possible. 
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Addendum 1: Research Plan Interview Script 
Date of Interview ~-/ __ /~- (dd/mm/yyyy) 
Time Interview Started __ h __ m 
Time Interview Ended __ h __ m 
Name of interviewer ___________ _ 
Introduction Script for Adults: 
Participant Study ID~~~~­
SARA ID·~----
Hello. My name is and I work with a research team at the Kalembe Lembe 
Hospital. Thank you for taking the time to speak with me about your experiences in providing 
HIV medicines to the child. I am very interested in learning more about what it is like to care for 
children who take these kinds of medicines. 
(For those with children 8-17 Years of Age. If only have children< 8 years of age, please skip 
to next paragraph) 
With your permission, I would also be interested in speaking with the child about his/her 
thoughts on taking medicine. I believe this will give helpful information about what it is really 
like to take these medicines. If he/she have not been told of the illness I will completely respect 
that and will not refer to HIV in any direct or indirect way. I will ONLY refer to HIV medicines 
(sometimes called ART) as 'medication', 'medicine' 'pills', 'vitamins' or whatever you would 
prefer. With your permission, I would like to ask him or her to participate by answering these 
questions. If you would prefer that he/she not to, that also is acceptable and will not affect your 
interview. 
Before l continue, please take a look over the consent forms. I will need your signed permission 
to continue with your interview and your signed permission to interview the child. These forms 
describe in-detail the purpose of the study, as well as the risks and benefits of participating in this 
study. If you cannot read or if you would prefer, I will read them out loud to you. Please make 
sure you understand these forms. I can help you if you have any questions or do not understand 
any part of the forms. 
(After consent is signed) 
· I realize that the HIV medication regimens are complicated and can be very hard for some 
children to take. It can also be common to miss scheduled doses and many caregivers like you 
have told me they worry about how hard it is to always give the HIV medicines to their child on 
schedule. I am very interested in hearing your opinion on this topic. There is no right or wrong 
answer. Please remember everything you say will be kept private and confidential. I will not 
reveal anything that you tell me to any of the doctors or nurses or other staff at the clinic or to 
anyone else. As the consent forms mentioned, I will give a code to this interview so that no 
information that can identify you (like your name or birth date or address) can be linked to 
anything you say here. What you have to say is very important to me, but you do not have to 
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answer any question that makes you feel uncomfortable. If you do not wish to answer a question, 
let me know and I will move on to the next question. 
Before I begin the interview, do you have any questions for me? 
Also, would you like a snack or a drink at this time? There will be a short break during the 
interview for another snack, if you like. 
First I would like to ask you some questions about you, your household, and your relationship 
with the child. Then I will move on to questions about the child's medication. 
I. Background Information (To be asked of the adults only) 
1. Please tell me your age at your last birthday __ (years) 
2a. Have you ever attended school? Yes ...... 0 No ...... 1 Unknown ....... 2 
(lf2a is answered as yes) 
b. What grade did you complete? ____ _ 
3. Please tell me your exact relation to the child 
Mother. .......................... 0 Uncle ................................ .5 
Father ............................ 1 Grandmother. ....................... 6 
Sister. ............................ 2 Grandfather. .. .. .. .. .. .. .. .. .. .. .. . 7 
Brother ........................... 3 Non-relative .......................... 8 
Aunt.. ........................... 4 Other Relative ....................... 9 
Unknown ....................... 88 
If Other Relative please specify or General Comments: 
4. If not a relative, how long have you known the child? __ (months, years) N/A 
(Can skip if caregiver is mother) 
5. How would you rate the condition of the child's health at this time? (please circle one) 
Very poor ......................................... 0 Quite Good ......................................... 3 
Poor. . . . .. . . . . . .. .. . . . . . . . . . . .. . . .. .. . .. . . . . .... .. .. 1 Excellent .......................................... 4 
Moderate ......................................... 2 Don't know ........................................ 5 
6. a. How old is the child? (months or years) 
b. What sex is the child? 0 ............ Male 1.. ........... Female 
c. What year in school is the child. or if not in school, what level did they complete? __ _ 
7a. Would you say that you are the primary person who provides care for the child? 
Yes ...... O No ...... 1 Don't know ...... 88 
7b. Please tell me who is the primary person who cares for the child (if not you) or other people who provide care 
for the child (May circle more than one) 
Mother ........................... o Uncle ................................ 5 
Father. ........................... ! Grandmother. ...................... 6 
Sister ............................ .2 Grandfather. .. .. .. .. .. .. .. .. .. .. .. . 7 
Brother ........................... 3 Non-relative .......................... 8 
Aunt ............................. 4 Other Relative ....................... 9 
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If Other Relative please specify or General Connnents: 
Sa. Has anyone disclosed the HIV status to the Child? 
Yes ...... 0 (see -7 8b) No ...... 1 Unknown ...... 2 
Unknown ....................... ss 
Sb. If yes, what relationship to the child did the person who told them about their HIV status have? 
9a. Would you be willing to tell me if you, or anyone else in the home, besides the child, are living with HIV? 
Yes ...... O (see-7 9b) No ...... ! 
9b. Please list the relation(s) to the child of those people in the home who are living with HIV 
II. Qualitative Interview with Adult Caregivers Script 
Ql. Please tell me about the role you play in this child's life. 
Probes: 
1) Tell me about times that you spend with the child during a typical day 
-How would you describe the amount of time you spend with the child in general? 
-How much time per day do you spend with each other? 
-How many days out of the week do you generally see the child? 
2) What kinds of things do you do for this child? 
3) What kinds of things do you do with this child? 
Q2. Describe to me how the child gets and takes his/her medicines each day. 
Probes: 
1) Tell me about your role in providing the child's medication 
-How often are you present when the child takes his/her medications? 
2) Tell me about other people who provide the child with medication 
-Will you describe the role of other people who help provide medication? 
3) Tell me about the child's role in taking his/her medicines on his/her own 
4) Describe to me how you, or other caregivers, know the child has taken the medication 
-How do you know if they have actually swallowed it? 
Q3a. (If child's HIV status is revealed to them as per Part I, Question 7 answered yes) 
Please describe the situation when the child was told that he/she has HIV 
Probes: 
1) Tell me why you, or the person who told the child, felt that he/she needed to know at that point 
2) Describe the child's reaction to finding out that he/she has HIV 
3) Describe how the child feels about having HIV, at the present time 
4) How does the child cope with living with HIV at the present time? 
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Q3b. (If child's HIV status is not revealed to them as per Part I, Question 7 answered no) 
Please tell me about why you feel the child should not know they have HIV at this point in time 
Probes 
1) What do you tell the child when they ask about the purpose of these medications? 
2) What does your child suspect about his/her medications? 
-Tell me about things he/she has said about his/her medications 
-Do you think that he/she suspects that he/she has HIV? 
3) Please describe to me situations in which the child has questioned these medications 
-What prompted the child to ask questions? 
-How did you or others respond when this happened? 
4) Tell me about any plans you have to reveal at some time to the child that he/she has HIV 
-Why do you feel it will be appropriate then? (If have plans to tell at some point). 
Q4. Describe what you believe the HIV medication does for the child 
Probes: 
1) How do you think the HIV medication is helping the child? 
-How was the child before the medications? 
2) How do you think the HIV medication is hurting the child? 
-Tell me about bad things that have happened because of the medication 
3) What are your motivations for making sure the child gets their medication? 
Q5. Tell me how HIV/AIDS has affected your child 
Probes: 
1) How do you think their life is different with HIV/AIDS compared with children who do not have 
HIV/AIDS? 
2) What do you believe happens to children with HIV/AIDS? 
Q6. What does being 'adherent' to HIV medications mean to you? 
(Please ask all of these) 
a. What does following the doctor's recommendations mean to you? 
b. What does missing a dose mean to you? 
c. What happens when the child misses a dose? 
-What do you think about the effects of missing one dose on the child's health? 
-How does the child make-up for a missed dose, if at all? 
d. What does taking the medicine "on time" mean to you? 
-How is the timing of taking the medicine important, if at all? 
-How do you and the child plan the timing of his/her medications? 
-Does he/she take them at the same time every day? 
Q7a. Please give me your opinion of how many doses of HIV medication the child could miss and still be called 
'adherent' to medications 
LIST: (ask all options; define 'dose' as the full regimen of medications, not just some 
medications) 
Never misses a dose 
Misses no more than 1 dose per month 
Misses no more than 1 dose per week 
Misses no more than 1 dose per day 
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Misses no more than 2 doses per day 
Other ________ ~ 
b. How many doses do you think the child could miss in a (day, week) and still have your doctor say the child is 
doing a good job taking their medications?_~ 
Q8. Please tell about a typical day for the child and how he/she fits medications into that day. 
You are doing great with these questions. We are getting close to half way done. First, would 
you like another snack or anything else to drink? 
Q9. What kinds of things make it hard for the child to take the medication? 
QJO. What things about the medications themselves make them difficult to take? 
Probes: 
1) How do you and the child overcome taking medication that is complicated and must be taken in a 
specific way? 
2) Tell me about any side effects which have made taking medications difficult. 
3) How has their taste made them more difficult to take? 
Q.ll Tell me about anything else you can think of that makes it difficult for your child to take their HIV medicine 
Probes: 
1) Does medication ever get misplaced or lost? 
2) Tell me about when you or your child forgets to take his or her medicine 
3) Tell me about times you are unable to make clinic visits or get medication refills 
4) Other things? 
Ql2. Tell me about things which have made it easier for the child to take HIV medication 
Probes: 
I) How has the support from the family helped? 
2) What motivation do you get from thinking that the ART is helping the child to be healthy? 
3) How has support from the community helped? 
(Questions 13 -17 can serve to explore topics not mentioned in questions 9-12. If the interviewee talks a lot about 
one particular topic, you do not need to ask it again in the following questions) 
QI3. Tell me about how issues with money affect obtaining HIV medications and the child taking their HIV 
medications, if at all. 
Probes: 
I) Can you describe other expenses you or your family has because the child has HIV, besides the 
medications? 
2) If you had more money, how would it be easier to provide HIV medications for your child and for 
him/her to take these medications? 
64 
Ql4. Please tell me how attitudes about HIV from the people in your community or your society about HIV affects 
your child being able to take his/her medication 
Probes: 
1) Describe how your community views the HIV/AIDS epidemic 
2) How does your community feel about children living with HIV? 
Q15. How does your family's work schedule or your child's school schedule affect his/her ability to take HIV 
medication? 
Probe: 
1) How does the absence of parent or family member around make it more difficult for your child to take 
HIV medication? 
2) How does going to school make it more difficult for your child to take medications? 
Ql6. How does the child's living situation make it more difficult to take medications? 
Probe: 
1) Tell me about whether other children who live with this child might make it difficult for the child to take 
medications 
2) Tell me about anyone else the child lives with who makes it difficult to take HIV medicine 
3) How is it difficult for the child to follow a medication schedule in his or her living environment? 
4) Is there a particular time of day the child has trouble taking medications? 
Q 17. Tell me about any aspects to your medical care you receive at Kalembe Lembe which make it harder for your 
child to take medication 
Probe: 
1) Tell me how your relations with the doctors, nurses, and counselors can make it harder for the child to 
take his/her medications 
-What are bad things about your relations with these people? 
-What are good things about your relations with these people? 
2) Tell me about your attitudes towards western medicine 
-Does this make it harder for you, the child, or anyone else in the family to take HIV medications? 
3) How has the medical care you received helped, if at all? 
4) How do you feel about the instructions you get about these regimens? 
Q 18a. (If child's HIV status is revealed to them as per Part I, Question 8 answered yes) 
Since your child has been told he/she has HIV and that is why he/she must take medications, please tell me how you 
think this helps or hurts your child in taking HIV medications 
Probes: 
1) Is he/she more motivated because of this? 
2) Because he/she understand it, is he/she more willing? 
3) Does the child get frustrated taking his/her medication? 
Q18b. (If child's HIV status is not revealed to them as per Part I, Question 8 answered no) 
Since your child has not been told that he/she has HIV and he/she doesn't know the true purpose of his/her 
medications, please tell me how you think this helps or hurts your child in taking his/her HN medications 
Probes: 
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1) Does he/she have trouble getting motivated to take his/her medication? 
2) Does he/she ever simply not want to take his/her medications? 
3) Does the child get frustrated taking his/her medication? 
Ql9. Tell me about any specific strategies you or the child have used to take medications every day and on time. 
Probes: 
1) Please give me specific examples 
-Have you used alarm clocks? 
-Do you place the pills in a special place? 
-Do you keep a log? 
-Any other special reminders? 
Q20. What responsibility do you believe your community (for example fantily, friends, and neighbors) have in 
helping the child to take their mv medication, if any? 
Probe 
1) If none, do you believe the community should play a role? 
2) If none, what impedes the community from playing a role in helping your child to take medication? 
Q21. (Ask if the Section I, question 8 is yes AND the caregiver listed him or herself as HIV positive) 
Can you please tell me how your experience with mv has helped your child to cope with his/her illness and to take 
medications? 
We have almost completed the interview. Thank you for your patience in answering these 
questions. Finally, we would like to specifically ask whether the child has missed any recent 
doses of HIV medication. I know that most people have trouble taking all of their medication 
exactly as recommended. Please tell me what you are actually doing. Don't worry about telling 
me that you don't take all your pills or medicines. I need to know what is really happening, not 
what you think I want to hear. 
Q22. Can you tell me about any doses the child has missed recently? 
(Please ask all the following) 
a. Thinking back to yesterday, how many doses of his/her medicines did the child miss yesterday? 
b. How about the day before that? And the day before that? 
c. Specifically, which doses did he/she miss? (For example morning, afternoon, or night) 
d. Because the child takes several different medications, is there one that he/she tends to miss most often? 
e. Has the child missed any doses in the last week? Can you tell me how many? 
d. Has the child missed any doses in the last month? Can you give me an idea of how many? 
Thank you very much for answering our questions. I appreciate that you took the time to answer 
them. This concludes our interview and you are free to go. 
III. Qualitative Interview Script for Children who DO know their HIV Status 
Hello. My name is and I work with a medical research team at the 
Kalembe Lembe Hospital. I would like to talk with you today about your experiences in taking 
66 
your HIV medicine. I am very interested in learning more about what it is like for you to take 
this. Would it be ok for me to ask you some questions? 
~(If child is 13 years of age or older and assent form is needed). 
Let me begin with some information about these questions. They are part of a study run by the 
clinic, the hospital, and the University of North Carolina, in the United States. Since you are old 
enough to make decisions for yourself, I would like you to look over a form which gives you 
some details on the types of information I will be asking about. I will ask that you sign the form 
in order to give me permission to ask you questions. This form will tell you about the purpose of 
this study, as well as some risks and benefits of participation this study. If you would prefer, I 
can read it out loud to you. I can help you if you have any questions or do not understand any 
part of the forms. 
-7(If child is younger than 13 years of age and no assent form needed) 
Let me begin with some information about these questions. They are part of a study run by the 
clinic, the hospital, and the University of North Carolina, in the United States. These questions 
will ask you about your relationship with the person who brought you to clinic today, your 
thoughts about HIV and the medicine you take for it, as well as things that make it harder or 
easier to take your medications. This will take between 30 minutes and an hour and a half. Is it 
ok with you to continue? 
(After assent given) 
I realize that taking your HIV medicine every day can be really hard. It can also be common to 
miss scheduled doses. Young people like you have told me that they worry about how hard it is 
to always take their medicine on schedule. I am very interested in hearing your opinion on this 
topic, so there are no right or wrong answers. Please be reminded that everything you say will 
be kept private and confidential. I will not tell anything you say to the doctors or nurses or other 
staff, not even with the person who brought you to clinic, or with other family members or 
friends. I will give a special code to this interview and no information that can identify you (like 
your name or birth date) can be linked to anything you say here. You are not required to answer 
any question you do not feel comfortable with. If you do not wish to answer a question, let me 
know and I will move on to the next question. 
Before I begin the interview, do you have any questions for me? 
First I would like to ask you a few questions about yourself. 
Q.O How old are you? (months or years) 
What sex is the child (please make an observation, do not ask unless unsure) 
0 ............ Male 1.. ........... Female 
What year in school are you, or if not in school, what level did you complete? __ _ 
Ql. Can you tell me about your relationship with the person who brought you to clinic today? 
Probes: 
1) What is their relation to you? 
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2) Tell me about a typical day you spend with this person 
-How much time per day do you spend with each other? 
-How many days out of the week do you see this person? 
Q2. Can you describe to me who helps you the most with taking your pills 
Probes: 
1) Do you or someone else have most the responsibility in taking your pills? 
2) Can you describe all the people who help you take your pills? 
Q3. Please tell me about a typical day taking your pills 
Probes: 
1) Can you tell me about your routine? 
2) How many times do you take pills each day? How many pills each time? 
Q4. Can you describe your role in taking your pills? 
Probes: 
1) Does someone else remind you to take pills, or do you remind yourself? 
2) How do you get your pills every day? 
-Who gives them to you to take? 
3) Does anyone else besides you check to see if you have taken your pills? 
-If so, how do they check? 
QS. Please tell me what you know about HIV 
Probes: 
I) What have you learned about HIV? 
2) What have people told you about HIV that you think is wrong? 
Q6. Tell me what you remember about finding out that you had HIV 
Probes: 
1) How did you find out? 
2) How long have you known? 
3) How did you feel when you were told? 
4) Are you glad you know? 
-Why or why not? 
Q7. Tell me what you think about your HIV medications 
Probes: 
I) What do you believe these pills do for you? 
2) How do these medications help you? 
3) How do these medications hurt you? 
4) Do you trust these medications? 
-Why or why not? 
5) How long do you think you will have to take these pills? 
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6) Do you like taking your medications? 
-Tell me why or why not 
You are doing great with these questions. We are about halfway done. First, would you like 
another snack or anything else to drink? 
Q8. What kinds of things make it hard for you to take your medication? 
Q9. What is it about the medicine themselves that make them harder to take? 
Probes: 
1) Tell me about how side effects make it harder to take your pills 
2) Tell me about how taste makes it harder to take your pills. 
-Are your pills or the liquid hard to swallow? 
3) Tell me how taking your pills multiple times per day makes it harder. 
(Questions 10 -13 can serve as probes to Question 8-9. If the interviewee talks a lot about one particular topic, you 
do not need to ask it again in the following questions) 
QlO. (If the child goes to school) Tell me how going to school makes taking your medication harder 
Probes: 
1) What do people at your school think about other kids with HIV? 
2) How do you try to hide taking your medicine at school? 
-Why do you do this? 
-Does this make taking your medicine more difficult? 
Q11. Tell me about things at home which make it harder to take you medications 
Probes: 
1) Tell me how other people in the home make it harder 
2) Does having lots of people around make it harder to take? 
-It is easier to forget or misplace medications? 
Q12. Tell me how your community makes it harder to take your medicine? 
Probes: 
1) Do you think people judge you for having HIV? 
-Tell me about that. 
2) How do people in your community make you feel about having HIV? 
-Do people know? 
3) Do these things make you want to hide taking your pills? 
-Why or why not? 
Ql3. You have mentioned some interesting things about taking your pills. What about for other people your age? 
Can you think of some things we didn't talk about that make taking HIV medicine harder for other people your age? 
(Not necessarily you) 
Probes: 
1) Is it easy to forget taking these pills? 
-Tell me about that 
69 
